Rimonabant is an anorectic anti-obesity drug developed by Sanofi-Aventis. It is marketed as Acomplia in the UK and EU. It has not got FDA (Food and Drug Administration) approval for sale in US. When Rimonabant gets approval from it for sale in US it might be marketed as Zimulti. Earlier the manufacturer claimed that with it one can get away from smoking habit but recently they are keeping quite on that claim. Even their website dedicated to Rimonabant (Acomplia) skips that topic.
Rimonabant is a CB1 blocker by nature. It selectively blocks CB1 receptors found in brain and other organs nearby which regulate glucose and lipid metabolism. The drug helps in decreasing the over activity of EC (endocannabinoid) system. EC is responsible is a physiological system which plays an important role in controlling energy balance and body weight. Nausea, headache, dizziness and depression are some of the common side effects associated with the intake of Rimonabant. However, the side effects are mild and are for short period only.
A person should always consult a doctor before going for the drug. A doctor is the right person to decide what will work out for him. Children, breast feeding mothers and pregnant women should consult a doctor before taking the drug. Persons with heart ailments, diabetes, asthma, allergy or blood pressure should tell their doctor prior to the medication of Rimonabant (Acomplia). As the introduction of the drug is new the results of its effect are not available now. But with time the results will be visible. As of now, it is hard to find pharmacists who sell it in the UK or EU so online pharmacies are the best option to buy Rimonabant.
Obesity is a wide spread disease spanning across all ages throughout the world. To stop it, Rimonabant diet pill helps an individual by suppressing his appetite for food intake. But the real medicine lies in the exercises and the controlled diet program that one follows with Rimonabant.
Other Weight Loss Resources
Acomplia
Acomplia diet pill
Source:-www.ideamarketers.com
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment